Aspirin Scam Exposed

Millions swallow aspirin daily chasing colon cancer protection, but a landmark review reveals bleeding risks hit immediately while benefits hide—if they exist—in uncertain shadows after 15 years.

Story Snapshot

Cochrane review of 10 RCTs with 124,837 average-risk participants finds no reliable colorectal cancer reduction in 5-15 years.
Serious bleeding and hemorrhagic stroke risks start day one, outweighing unproven long-term gains.
Focuses on average-risk adults, not high-risk groups like Lynch syndrome.
Urges personalized decisions over blanket aspirin use for prevention.
Shifts emphasis to lifestyle, screening, and evidence-based alternatives.

Cochrane Review Exposes Aspirin Limits

Researchers at West China Hospital, Sichuan University, led by Dr. Zhaolun Cai and Dr. Bo Zhang, analyzed 10 randomized controlled trials. These trials included 124,837 participants at average risk for colorectal cancer. Follow-up periods ranged 5-15 years, with most using low-dose aspirin of 75-100mg daily. The review found no significant drop in cancer incidence or mortality during this time. Long-term data beyond 15 years relied on biased observational follow-ups, rendering benefits highly uncertain.

Dr. Bo Zhang stated any potential preventive effect requires over a decade, while bleeding risks emerge immediately. Evidence rejects routine recommendations for average-risk individuals. This gold-standard Cochrane analysis prioritizes high-quality RCTs over weaker observational studies that fueled earlier hype.

Aspirin’s Historical Rise and Fall for Cancer Prevention

Aspirin’s anti-inflammatory action as an NSAID sparked interest in the 1990s-2000s. Observational studies hinted at lower colorectal cancer risk with prolonged use. Colorectal cancer struck 1.9 million new cases and over 900,000 deaths globally in 2022, mainly hitting those over 50. Early RCTs showed promise for high-risk Lynch syndrome patients or cancer recurrence prevention. Results stayed inconsistent for average-risk primary prevention.

No qualifying RCTs existed for non-aspirin NSAIDs in this group. Prevention guidelines stress diet, exercise, colonoscopy screening, and managing blood pressure or lipids. Aspirin avoids routine use even for primary heart disease prevention due to hemorrhage dangers.

Stakeholders Drive Evidence-Based Caution

Cochrane Collaboration published the review on March 4, 2026, earning instant media coverage from ScienceDaily and Medical News Today. Independent academic researchers hold no pharma ties. Their work influences bodies like USPSTF and NICE. Cancer Research UK agrees aspirin merits more study for treatment but echoes bleeding warnings. Healthcare providers now weigh individual risks over population-wide advice.

Media amplified Dr. Zhang’s call against blanket use. Patient advocates push trials for recurrence but align with caution for everyday folks.

Impacts Reshape Prevention Choices

Short-term, the review curbs self-prescribed aspirin, slashing bleeding events like extracranial hemorrhage and strokes. Long-term, guidelines may pivot from routine chemoprevention. Millions of prophylactic users rethink habits. High-risk groups see no change. Lifestyle and screening gain priority for those without heart disease.

Healthcare costs drop from avoided complications. Society benefits from ditching hype for informed choices, aligning with conservative values of personal responsibility. Pharma feels minimal hit from generic aspirin, but GLP-1 drugs for diabetes show 26-36% stronger risk cuts in real-world data, spurring oncology interest.